{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:15:39Z","timestamp":1788448539678,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Orthopedic Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ocl.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:23:03Z","timestamp":1784838183000},"page":"317-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like Peptide-1 Receptor Agonist Use May Reduce Disease Activity and Progression in Osteoarthritis and Inflammatory Arthritis"],"prefix":"10.1016","volume":"57","author":[{"given":"Maxwell","family":"Trudeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Schaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Schwarzkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ocl.2026.05.004_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41413-023-00301-9","article-title":"Risk of metabolic abnormalities in osteoarthritis: a new perspective to understand its pathological mechanisms","volume":"11","author":"Wei","year":"2023","journal-title":"Bone Res"},{"key":"10.1016\/j.ocl.2026.05.004_bib2","first-page":"121","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: a new opportunity?","volume":"32","author":"Meurot","year":"2022","journal-title":"J Orthop Transl"},{"issue":"5","key":"10.1016\/j.ocl.2026.05.004_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/annrheumdis-2019-216713","article-title":"Metformin limits osteoarthritis development and progression through activation of AMPK signalling","volume":"79","author":"Li","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.004_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J Am Pharm Assoc"},{"issue":"12","key":"10.1016\/j.ocl.2026.05.004_bib5","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2024.18219","article-title":"GLP-1 medication use for type 2 diabetes has soared","volume":"332","author":"Hegland","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ocl.2026.05.004_bib6","doi-asserted-by":"crossref","first-page":"q1645","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ocl.2026.05.004_bib7","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.004_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103864","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in rheumatology: a review of current evidence and future directions","volume":"24","author":"Bilgin","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.004_bib9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.24893","article-title":"2022 American college of rheumatology\/American Association of Hip and Knee Surgeons Guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","volume":"74","author":"Goodman","year":"2022","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.004_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23478","article-title":"Association of surgical experience with risk of complication in total hip arthroplasty among patients with severe obesity","volume":"4","author":"Charalambous","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10136","key":"10.1016\/j.ocl.2026.05.004_bib11","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van Den Bosch","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ocl.2026.05.004_bib12","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/acr.25175","volume":"75","author":"Hannon","year":"2023","journal-title":"Arthritis Care Res"},{"issue":"04","key":"10.1016\/j.ocl.2026.05.004_bib13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0040-1715098","article-title":"Gout as a predictor of total knee arthroplasty outcomes and costs","volume":"35","author":"Rosas","year":"2022","journal-title":"J Knee Surg"},{"issue":"8","key":"10.1016\/j.ocl.2026.05.004_bib14","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.arth.2023.01.064","article-title":"The effects of gout following total knee arthroplasty: a retrospective analysis","volume":"38","author":"Cole","year":"2023","journal-title":"J Arthroplast"},{"issue":"12","key":"10.1016\/j.ocl.2026.05.004_bib15","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/rheumatology\/key212","article-title":"Urate-lowering treatment and risk of total joint replacement in patients with gout","volume":"57","author":"Kuo","year":"2018","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.ocl.2026.05.004_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11926-017-0688-y","article-title":"Gout and metabolic syndrome: a tangled web","volume":"19","author":"Thottam","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.ocl.2026.05.004_bib17","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.semarthrit.2015.01.008","article-title":"Rheumatoid arthritis: perioperative management of biologics and DMARDs","volume":"44","author":"Goodman","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ocl.2026.05.004_bib18","first-page":"355","article-title":"Lower extremity arthroplasty in patients with inflammatory arthritis: preoperative and perioperative management","volume":"21","author":"Goodman","year":"2013","journal-title":"J Am Acad Orthop Surg"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.004_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41419-017-0217-y","article-title":"Glucagon-like peptide-1 receptor regulates endoplasmic reticulum stress-induced apoptosis and the associated inflammatory response in chondrocytes and the progression of osteoarthritis in rat","volume":"9","author":"Chen","year":"2018","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.004_bib20","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.ocl.2026.05.004_bib21","first-page":"4800","article-title":"Liraglutide suppresses TNF-\u03b1-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis","volume":"11","author":"Mei","year":"2019","journal-title":"Am J Transl Res"},{"issue":"4","key":"10.1016\/j.ocl.2026.05.004_bib22","first-page":"2081","article-title":"The protective effects of exenatide against AGEs-induced articular matrix degradation in human primary chondrocytes","volume":"11","author":"Tong","year":"2019","journal-title":"Am J Transl Res"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.004_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s12891-024-07640-6","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.ocl.2026.05.004_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.108968","article-title":"The protective effects of dulaglutide against advanced glycation end products (AGEs)-induced degradation of type - collagen and aggrecan in human SW1353 chondrocytes","volume":"322","author":"Li","year":"2020","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.004_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00011-025-02140-2","article-title":"The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review","volume":"74","author":"Buonanno","year":"2025","journal-title":"Inflamm Res"},{"key":"10.1016\/j.ocl.2026.05.004_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1016\/j.ocl.2026.05.004_bib27","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/dom.12985","article-title":"Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: an 8-week, randomised, open-label trial","volume":"19","author":"Tonneijck","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.004_bib28","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard-2023-223845","article-title":"Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort","volume":"82","author":"Zhu","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ocl.2026.05.004_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17581869.2024.2402214","article-title":"Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes","volume":"14","author":"Samajdar","year":"2024","journal-title":"Pain Manag"},{"issue":"10","key":"10.1016\/j.ocl.2026.05.004_bib30","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.arth.2024.06.008","article-title":"The five-year incidence of progression to osteoarthritis and total joint arthroplasty in patients prescribed glucagon-like peptide 1 receptor agonists","volume":"39","author":"Lavu","year":"2024","journal-title":"J Arthroplast"},{"key":"10.1016\/j.ocl.2026.05.004_bib31","series-title":"American College of rheumatology","article-title":"Treatment with the glucagon-like peptide-1 analogue liraglutide is associated with amelioration of disease activity in a prospective cohort study of patients with inflammatory arthritis","author":"Sullivan","year":"2013"},{"issue":"1","key":"10.1016\/j.ocl.2026.05.004_bib32","article-title":"Effects of liraglutide among patients with psoriatic arthritis and obesity","volume":"21","author":"Nicolau","year":"2025","journal-title":"Reumatol Cl\u00ednica Engl Ed"},{"key":"10.1016\/j.ocl.2026.05.004_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152807","article-title":"Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: a retrospective real-world analysis (URISEMA study)","volume":"74","author":"Moreno-P\u00e9rez","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ocl.2026.05.004_bib34","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/jdi.13314","article-title":"Evaluation of the efficacy of low-dose liraglutide in weight control among Taiwanese non-diabetes patients","volume":"11","author":"Chou","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"10","key":"10.1016\/j.ocl.2026.05.004_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13007","article-title":"Liraglutide relieves cardiac dilated function than DPP -4 inhibitors","volume":"48","author":"Hiramatsu","year":"2018","journal-title":"Eur J Clin Invest"},{"issue":"6","key":"10.1016\/j.ocl.2026.05.004_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1479164120971220","article-title":"Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment","volume":"17","author":"Hiramatsu","year":"2020","journal-title":"Diab Vasc Dis Res"},{"issue":"Suppl 2","key":"10.1016\/j.ocl.2026.05.004_bib37","first-page":"S133","article-title":"Potential link in cardiovascular protection for obese male type 2 diabetes mellitus patients treated with liraglutide","volume":"59","author":"Adropin","year":"2020","journal-title":"Acta Clin Croat"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.004_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ocarto.2022.100255","article-title":"Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: secondary analyses of a randomised controlled trial","volume":"4","author":"Bartholdy","year":"2022","journal-title":"Osteoarthr Cartil Open"},{"issue":"17","key":"10.1016\/j.ocl.2026.05.004_bib39","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ocl.2026.05.004_bib40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.004_bib41","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.ocl.2026.05.004_bib42","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.ocl.2026.05.004_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/dom.13541","article-title":"Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: a randomized, double-blind, placebo-controlled trial","volume":"21","author":"Liakos","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ocl.2026.05.004_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101088","article-title":"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study","volume":"39","author":"Ji","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ocl.2026.05.004_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/annrheumdis-2020-eular.3088","article-title":"OP0172 effect of weight loss and liraglutide on serum urate levels among obese knee osteoarthritis patients: secondary analysis of a randomised controlled trial","volume":"79","author":"Zobbe","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ocl.2026.05.004_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.diabres.2019.05.001","article-title":"Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: a post-hoc analysis of a 52-week randomised trial","volume":"153","author":"Muskiet","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.ocl.2026.05.004_bib47","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/jdi.13270","article-title":"Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: a randomized controlled study","volume":"11","author":"Nakaguchi","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"8","key":"10.1016\/j.ocl.2026.05.004_bib48","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1111\/bcp.15344","article-title":"The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: a systematic review and meta-analysis","volume":"88","author":"Najafi","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ocl.2026.05.004_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70103","article-title":"Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis","volume":"7","author":"Kellner","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ocl.2026.05.004_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105732","article-title":"The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"75","author":"Du","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"Supplement_1","key":"10.1016\/j.ocl.2026.05.004_bib51","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.2337\/dc25-S016","article-title":"16. Diabetes care in the hospital: standards of care in diabetes\u20142025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ocl.2026.05.004_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"4","key":"10.1016\/j.ocl.2026.05.004_bib53","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/SLA.0000000000006614","article-title":"Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes","volume":"281","author":"Aschen","year":"2025","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.ocl.2026.05.004_bib54","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1016\/j.arth.2025.07.015","article-title":"Impact of glucagon-like peptide-1 receptor agonists on postoperative outcomes in arthroplasty: a systematic review","volume":"40","author":"Lee","year":"2025","journal-title":"J Arthroplast"},{"issue":"21","key":"10.1016\/j.ocl.2026.05.004_bib55","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.5435\/JAAOS-D-24-01284","article-title":"The effects of glucagon-like peptide-1 agonist therapy on risk of infection, fracture, and early revision in primary total joint arthroplasty","volume":"33","author":"Levidy","year":"2025","journal-title":"J Am Acad Orthop Surg"},{"issue":"8","key":"10.1016\/j.ocl.2026.05.004_bib56","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.arth.2025.03.012","article-title":"GLP-1 agonists for weight loss: do they increase complications in non-diabetic patients undergoing primary total hip arthroplasty?","volume":"40","author":"Verhey","year":"2025","journal-title":"J Arthroplast"}],"container-title":["Orthopedic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003058982600074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003058982600074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:30:43Z","timestamp":1788445843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003058982600074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S003058982600074X"],"URL":"https:\/\/doi.org\/10.1016\/j.ocl.2026.05.004","relation":{},"ISSN":["0030-5898"],"issn-type":[{"value":"0030-5898","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like Peptide-1 Receptor Agonist Use May Reduce Disease Activity and Progression in Osteoarthritis and Inflammatory Arthritis","name":"articletitle","label":"Article Title"},{"value":"Orthopedic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ocl.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}